Palvella Therapeutics PVLA Debt-to-equity

Debt-to-equity at other companies

Relay Therapeutics, Inc.RLAY

0×0.0×

Viridian Therapeutics, Inc.VRDN

0.2×+0.1×

ANI PharmaceuticalsANIP

0.5×-0.2×

Arcutis Biotherapeutics, Inc.ARQT

0.5×-0.3×

Zevra Therapeutics, Inc.ZVRA

0×-0.5×

Eton Pharmaceuticals, Inc.ETON

1×-0.2×

FAQ

What is Palvella Therapeutics's debt-to-equity?

Palvella Therapeutics (PVLA) reported debt-to-equity of 0× in Q1 2026.

What is the long-term trend for Palvella Therapeutics's debt-to-equity?

Over 2 years (2020 to 2025), Palvella Therapeutics's debt-to-equity has grown at a -79.7% compound annual growth rate (CAGR), from 0.5× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.